CC chemokine ligand 21 enhances the immunogenicity of the breast cancer cell line MCF-7 upon assistance of TLR2

Carcinogenesis

Volumn 32, Issue 3, 2011, Pages 296-304

  Wu, S ^a,b   Lu, X ^a   Zhang, Z L ^a   Lei, P ^b   Hu, P ^c   Wang, M ^b   Huang, B ^b   Xing, W ^b   Jiang, X T ^a   Liu, H J ^d   Zhu, Z G ^d   Li, W H ^b   Zhu, H F ^b   Fu, N ^a   Shen, G X ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^d GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CYCLOPHOSPHAMIDE; FAS LIGAND; HLA ANTIGEN; HUMAN LEUKOCYTE ANTIGEN CLASS I; LIPOTEICHOIC ACID; MITOMYCIN C; SECONDARY LYMPHOID TISSUE CHEMOKINE; TOLL LIKE RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOLOGY; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TUMOR GROWTH; TUMOR IMMUNITY; UPREGULATION;

EID: 79952289512     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq265     Document Type: Article

References (32)

1. Forster, R. et al. (2008) CCR7 and its ligands: balancing immunity and tolerance. Nat. Rev. Immunol., 8, 362-371.
2. Mashino, K. et al. (2002) Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res., 62, 2937-2941.
3. Takeuchi, H. et al. (2004) CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin. Cancer Res., 10, 2351-2358.
4. Muller, A. et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature., 410, 50-56.
5. Chada, S. et al. (2003) Cytokine- and chemokine-based gene therapy for cancer. Curr. Opin. Mol. Ther., 5, 463-474.
6. Nomura, T. et al. (2000) Chemokines and anti-cancer immunotherapy: antitumor effect of EBI1-ligand chemokine (ELC) and secondary lymphoid tissue chemokine (SLC). Anticancer Res., 20, 4073-4080.
7. Zitvogel, L. et al. (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol., 6, 715-727.
8. Obeid, M. et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med., 13, 54-61.
9. Casares, N. et al. (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med., 202, 1691-1701.
10. Garay, R.P. et al. (2007) Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur. J. Pharmacol., 563, 1-17.
11. Wu, S. et al. (2008) Tumor transfected with CCL21 enhanced reactivity and apoptosis resistance of human monocyte-derived dendritic cells. Immunobiology., 213, 417-426.
12. Weng, X. et al. (2007) Peptide-dependent inhibition of alloreactive T-cell response by soluble divalent HLA-A2/IgG molecule in vitro. Transplantation., 84, 1298-1306.
13. Algarra, I. et al. (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother., 53, 904-910.
14. Agrawal, S. et al. (2004) Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell. Immunol., 228, 130-137.
15. Nagy, N. et al. (1998) Tumor surveillance: expression of the transporter associated with antigen processing (TAP-1) in ex-vivo human tumor samples and its elevation by in vitro treatment with IFN-gamma and TNFalpha. Immunol. Lett., 64, 153-160.
16. Ryan, A.E. et al. (2006) Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle., 5, 246-249.
17. Tindle, R.W. (2002) Immune evasion in human papillomavirus-associated cervical cancer. Nat. Rev. Cancer., 2, 59-65.
18. Ashour, A.E. et al. (2007) CCL21-induced immune cell infiltration. Int. Immunopharmacol., 7, 272-276.
19. Wang, J. et al. (2008) Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy. J. Natl Cancer Inst., 100, 502-512.
20. Gollmer, K. et al. (2009) CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood., 114, 580-588.
21. Damas, J.K. et al. (2009) Homeostatic chemokines CCL19 and CCL21 promote inflammation in human immunodeficiency virus-infected patients with ongoing viral replication. Clin. Exp. Immunol., 157, 400-407.
22. Asprodites, N. et al. (2008) Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J., 22, 3628-3637.
23. Komai-Koma, M. et al. (2004) TLR2 is expressed on activated T cells as a costimulatory receptor. Proc. Natl Acad. Sci. USA., 101, 3029-3034.
24. Brode, S. et al. (2006) Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol., 177, 6603-6612.
25. Scheithauer, W. et al. (2002) Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. Cancer Invest., 20, 60-68.
26. Shields, J.D. et al. (2007) Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell., 11, 526-538.
27. Shields, J.D. et al. (2010) Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science., 328, 749-752.
28. Stein, J.V. et al. (2000) The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules. J. Exp. Med., 191, 61-76.
29. Marcenaro, E. et al. (2009) Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction. Blood., 114, 4108-4116.
30. Braun, S.E. et al. (2000) The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J. Immunol., 164, 4025-4031.
31. Bogunovic, D. et al. (2009) Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc. Natl Acad. Sci. USA., 106, 20429-20434.
32. Hillinger, S. et al. (2006) CCL19 reduces tumour burden in a model of advanced lung cancer. Br. J. Cancer., 94, 1029-1034.